Celldex Therapeutics
Clinical trials sponsored by Celldex Therapeutics, explained in plain language.
Biotech developing immunotherapies for cancer and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New hope for chronic hive sufferers: drug shows promise in major trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New asthma drug enters early human safety testing Results expected Mar 2027 (estimated)
-
New hope for chronic hives: barzolvolimab shows promise in Long-Term trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of barzolvolimab in adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. Participants have already completed earlier phase 3 trials. The goal is to see how well the drug control…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for chronic hive sufferers: drug shows promise in major trial
Disease control OngoingThis study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (CSU), a condition causing long-term hives and itching that doesn't get better with standard antihistamines. About 963 adults will receive either the drug or a placebo to see if it redu…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThis phase 3 study tests barzolvolimab, a new biologic drug, in 976 adults with chronic spontaneous urticaria (CSU) whose hives and itching persist despite antihistamines. Participants receive either barzolvolimab or a placebo by injection. The main goal is to see if the drug red…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eczema drug shows promise in reducing itch and rash
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose,…
Phase 2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New shot aims to stop the itch of prurigo nodularis
Symptom relief OngoingThis phase 2 trial tests a drug called barzolvolimab in 140 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug reduces itch severit…
Phase 2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC